BlossomHill Therapeutics Stock (BLSM) Fails to Shine After $150M U.S. IPO

Shares in cancer-focused biotech firm BlossomHill Therapeutics ($BLSM) dropped nearly 3% in its stock market debut after it raised $150 million in ...

Keep Reading →